The Cure Cjd Campaign

Although little-known to the public, prion diseases account for roughly one death in every and one in UK citizens may be carriers of the disease. They are rare but invariably fatal neurodegenerative disorders of the brain, which cause rapid physical and mental decline, inevitably leading to death. These diseases include Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler-Scheinker syndrome (GSS) and Fatal Familial Insomnia (FFI), and can be sporadic, genetic or acquired. PRN100 is the result of three decades of ground-breaking research conducted by the MRC Prion Unit at University College London Hospitals (UCLH). A small treatment program administered PRN100 to six patients with CJD. The results, published in the world’s leading neurology journal The Lancet Neurology (2022), were described as very encouraging and concluding: “It will be important to now evaluate PRN100 in a regulated phase 2 study […]” The next crucial step is the Phase II clinical trial, which will demonstrate the treatment’s efficacy. After 30 years of dedicated research, just a few final steps remain to turn hope into reality — to transform the lives of patients, at-risk populations, families, carers and society as a whole, while also paving the way for advances benefiting prion-like conditions such as Alzheimer’s and Parkinson’s disease.